Nuvilex (NASDAQ:PMCB) CEO Purchases $33,200.00 in Stock

Nuvilex Inc. (NASDAQ:PMCB) CEO Joshua Silverman purchased 40,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 7th. The stock was purchased at an average price of $0.83 per share, for a total transaction of $33,200.00. Following the purchase, the chief executive officer owned 416,250 shares in the company, valued at $345,487.50. This represents a 10.63% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Joshua Silverman also recently made the following trade(s):

• On Monday, January 5th, Joshua Silverman acquired 30,000 shares of Nuvilex stock. The shares were purchased at an average price of $0.78 per share, with a total value of $23,400.00.

Nuvilex Stock Up 7.5%

Nuvilex stock traded up $0.06 during trading hours on Wednesday, hitting $0.83. The stock had a trading volume of 296,817 shares, compared to its average volume of 292,514. The stock’s 50-day moving average price is $0.85 and its 200-day moving average price is $0.95. The stock has a market capitalization of $8.41 million, a P/E ratio of -0.60 and a beta of 0.04. Nuvilex Inc. has a 12-month low of $0.63 and a 12-month high of $1.90.

Nuvilex (NASDAQ:PMCB) last announced its quarterly earnings results on Thursday, December 18th. The company reported ($0.32) earnings per share for the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Nuvilex in a report on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

About Nuvilex

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte.